Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025

Vinge has advised Stirling Square Capital Partners (“SSCP”) in connection with the sale of part of its holding in Infobric to KKR

Pursuant to the transaction, KKR has become a significant owner, while SSCP will remain the largest owner.
October 15, 2025

Vinge advises Sertion in connection with the acquisition of Kiefer System Group

Vinge has advised Sertion AB (“Sertion”) in connection with the acquisition of Kiefer System Group.
October 10, 2025